Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Accounts Payables (2016 - 2025)

CorMedix's Accounts Payables history spans 13 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 358.37% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, up 358.37%, while the annual FY2025 figure was $7.9 million, 358.37% up from the prior year.
  • Accounts Payables for Q4 2025 was $7.9 million at CorMedix, down from $20.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $20.5 million in Q3 2025 and bottomed at $943344.0 in Q2 2021.
  • The 5-year median for Accounts Payables is $2.2 million (2022), against an average of $3.5 million.
  • The largest annual shift saw Accounts Payables crashed 44.27% in 2021 before it surged 1422.09% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $2.2 million in 2021, then fell by 0.34% to $2.2 million in 2022, then grew by 8.35% to $2.4 million in 2023, then decreased by 27.92% to $1.7 million in 2024, then soared by 358.37% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Accounts Payables are $7.9 million (Q4 2025), $20.5 million (Q3 2025), and $5.8 million (Q2 2025).